Business Description
Rakovina Therapeutics Inc
NAICS : 541714
SIC : 3741
Description
Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.01 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.36 | |||||
| Debt-to-EBITDA | -0.64 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 100 | |||||
| 14-Day RSI | 100 | |||||
| 6-1 Month Momentum % | 33.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.89 | |||||
| Quick Ratio | 1.89 | |||||
| Cash Ratio | 1.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -0.88 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -74.76 | |||||
| ROA % | -52.19 | |||||
| ROIC % | -58.51 | |||||
| ROC (Joel Greenblatt) % | -1719.23 | |||||
| ROCE % | -50.89 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.33 | |||||
| EV-to-EBIT | -2.02 | |||||
| EV-to-EBITDA | -2.52 | |||||
| EV-to-FCF | -3.67 | |||||
| Earnings Yield (Greenblatt) % | -49.5 | |||||
| FCF Yield % | -27.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:RKVTF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rakovina Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.028 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 100 | ||
| 14-Day ATR ($) | 0.000012 | ||
| 20-Day SMA ($) | 0.08 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 0.06 - 0.08 | ||
| Shares Outstanding (Mil) | 90.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rakovina Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rakovina Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Rakovina Therapeutics Inc Frequently Asked Questions
What is Rakovina Therapeutics Inc(RKVTF)'s stock price today?
The current price of RKVTF is $0.08. The 52 week high of RKVTF is $0.08 and 52 week low is $0.06.
When is next earnings date of Rakovina Therapeutics Inc(RKVTF)?
The next earnings date of Rakovina Therapeutics Inc(RKVTF) is .
Does Rakovina Therapeutics Inc(RKVTF) pay dividends? If so, how much?
Rakovina Therapeutics Inc(RKVTF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers